About Tricarboxylate transport protein, mitochondrial
Tricarboxylate transport protein, mitochondrial (SLC25A1) is a protein
from Homo sapiens identified by UniProt accession
P53007, 311 residues long.
MolForge cross-references it against 0 known binders and
106 disease associations.
Target properties
| Protein name | Tricarboxylate transport protein, mitochondrial |
|---|
| UniProt accession | P53007 |
|---|
| Gene | SLC25A1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 311 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (106)
Diseases linked to this target (Open Targets).
- D,L-2-hydroxyglutaric aciduria · score 0.81
- Presynaptic congenital myasthenic syndromes · score 0.64
- 2-hydroxyglutaric aciduria · score 0.51
- genetic disorder · score 0.41
- mitochondrial disease · score 0.37
- neurodegenerative disease · score 0.31
- amino acid measurement · score 0.17
- blood metabolite measurement · score 0.17
- protein measurement · score 0.17
- coronary artery calcification · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P53007-F1 | alphafold | PREDICTED | 74.72 | — |
Amino-acid sequence (311 residues)
MPAPRAPRAL AAAAPASGKA KLTHPGKAIL AGGLAGGIEI CITFPTEYVK TQLQLDERSH PPRYRGIGDC VRQTVRSHGV LGLYRGLSSL LYGSIPKAAV RFGMFEFLSN HMRDAQGRLD STRGLLCGLG AGVAEAVVVV CPMETIKVKF IHDQTSPNPK YRGFFHGVRE IVREQGLKGT YQGLTATVLK QGSNQAIRFF VMTSLRNWYR GDNPNKPMNP LITGVFGAIA GAASVFGNTP LDVIKTRMQG LEAHKYRNTW DCGLQILKKE GLKAFYKGTV PRLGRVCLDV AIVFVIYDEV VKLLNKVWKT D
Explore Tricarboxylate transport protein, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets